Sign in

CIK 0001501697

  • Non-accelerated filer
  • Smaller reporting company

X4 Pharmaceuticals, Inc

Sign in to watch
Ticker
XFOR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
273181608
Phone
+1 857-529-8300
Business address
61 NORTH BEACON STREET, 4TH FLOOR, BOSTON, MA, 02134
Former names
Arsanis, Inc.
Open-market buys, last 90 days
$11,884
in 1 filing
Open-market sales, last 90 days
$33,658
in 1 filing

Net −$21,775. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. KIRSKE DAVID −$34K Chief Financial Officer sold 7% of stake
  2. Craig Adam R +$12K Executive Chairman 1 filing
Date Insider Transaction Shares Price Value Owned after
2017-11-20 EMBL Technology Fund II GmbH & Co. KG 10% owner Purchase +20,000 $10.00 $200K 370,454
2017-11-20 EMBL Technology Fund II GmbH & Co. KG 10% owner Conversion · Series C Convertible Preferred Stock −207,253 0
2017-11-20 EMBL Technology Fund II GmbH & Co. KG 10% owner Conversion · Series D Convertible Preferred Stock −843,613 0
2017-11-20 NeoMed Innovation V L.P. 10% owner Conversion +246,682 246,682
2017-11-20 NeoMed Innovation V L.P. 10% owner Conversion +41,878 288,560
2017-11-20 NeoMed Innovation V L.P. 10% owner Conversion +279,079 567,639
2017-11-20 NeoMed Innovation V L.P. 10% owner Purchase +300,000 $10.00 $3.0M 867,639
2017-11-20 NeoMed Innovation V L.P. 10% owner Conversion · Series B Convertible Preferred Stock −552,487 0
2017-11-20 NeoMed Innovation V L.P. 10% owner Conversion · Series C Convertible Preferred Stock −84,040 0
2017-11-20 NeoMed Innovation V L.P. 10% owner Conversion · Series D Convertible Preferred Stock −952,497 0
2017-11-20 GV 2016 GP, L.L.C. 10% owner Conversion +451,362 451,362
2017-11-20 GV 2016 GP, L.L.C. 10% owner Conversion · Series D Convertible Preferred Stock −1,540,499 0
2017-11-20 Nessi Claudio Director Conversion +246,682 246,682
2017-11-20 Nessi Claudio Director Conversion +41,878 288,560
2017-11-20 Nessi Claudio Director Conversion +279,079 567,639
2017-11-20 Nessi Claudio Director Purchase +300,000 $10.00 $3.0M 867,639
2017-11-20 Nessi Claudio Director Conversion · Series B Convertible Preferred Stock −552,487 0
2017-11-20 Nessi Claudio Director Conversion · Series C Convertible Preferred Stock −84,040 0
2017-11-20 Nessi Claudio Director Conversion · Series D Convertible Preferred Stock −952,497 0
2017-11-20 Anna-Maria & Stephen Kellen Foundation, Inc. 10% owner Conversion +25,819 25,819

Page 15 of 25 · 490 trades